• DOI:10.1016/S0140-6736(20)30414-1
Corpus ID: 212745024

Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial

@article{Biswal2020EfficacyOA,
  title={Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial},
  author={Shibadas Biswal and C. Borja-Tabora and Luis Martinez Vargas and Derek Wallace},
  journal={The Lancet},
  year={2020},
  volume={395},
  pages={1423-1433}
}

Shibadas Biswal, C. Borja-Tabora, +1 author Derek Wallace

Published 2020

Medicine

The Lancet

BACKGROUND A substantial unmet need remains for safe and effective vaccines against dengue virus disease, particularly for individuals who are dengue-naive and those younger than 9 years. We aimed to assess the efficacy, safety, and immunogenicity of a live attenuated tetravalent dengue vaccine (TAK-003) in healthy children aged 4-16 years. METHODS We present data up to 18 months post-vaccination from an ongoing phase 3, randomised, double-blind trial of TAK-003 in endemic regions of Asia and… CONTINUE READING

View on Elsevier

arca.fiocruz.br

Save to Library

Create Alert

Cite

Launch Research Feed